Beactica’s proprietary and SPR-based small molecule drug discovery platform enables more efficient lead identification and optimization by giving a unique understanding of how compounds interact with its target protein. Beactica identifies and optimizes selective lead compounds with a high development potential and a reduced risk of failure in both early and late stages of the drug discovery process.
Key benefits include:
- Wide range of targets amenable (structural determination not necessary)
- High-quality interaction data for confident decisions (kinetics and selectivity)
- Unique structural interpretation of interaction data
- Very low protein consumption
Beactica's fragment-based approach works also when protein crystallisation is not possible. This means we can support you on a wider range of protein targets.